GW Pharmaceuticals plc
GW Pharmaceuticals has subsidiaries both in the US and UK. These sites allow the distribution of their plant-derived cannabinoid medication. Founded in 1998, the company has a reputation for developing close partnerships with medical regulatory bodies. They are responsible for producing the world’s first cannabinoid-based medication Sativex, and the FDA-approved CBD medication Epidiolex.
GW Pharmaceuticals has subsidiaries both in the US and UK. These sites allow the distribution of their plant-derived cannabinoid medication. Founded in 1998, the company has a reputation for developing close partnerships with medical regulatory bodies. They are responsible for producing the world’s first cannabinoid-based medication Sativex, and the FDA-approved CBD medication Epidiolex.
| Exchange | Symbol | Volume (24h) | Volume (%) | Price |
|---|---|---|---|---|
|
|
GWPH |
$0
|
0% |
$219.4800
|
